On November 10, 2017 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that it will present nonclinical data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) which demonstrate the potential for PEGPH20, Halozyme’s pegylated recombinant human hyaluronidase, to increase the infiltration of immune cells into the tumor microenvironment and enhance the efficacy of immuno-oncology drugs in an HA-accumulating murine colon tumor model (Press release, Halozyme, NOV 10, 2017, View Source [SID1234521938]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The study shows that degradation of hyaluronan (HA) in a tumor by PEGPH20 can facilitate an anti-tumor immune response induced by checkpoint blockade by promoting effector cell infiltration and skewing the immune microenvironment toward a more anti-tumor composition. The data support Halozyme’s ongoing clinical evaluation of PEGPH20 in combination with checkpoint inhibitors.
The poster, entitled "Degradation of hyaluronan by PEGPH20 promotes anti-tumor immunity and enhances the effect of checkpoint blockade in an HA-accumulating mouse syngeneic tumor model," will be presented as part of a series of posters focusing on the tumor microenvironment from 12:30 p.m. to 2 p.m. EST on Saturday, November 11.